GLENMARK Intraday Analysis...

GLENMARK Share Price

Open 884.80 Change Price %
High 897.00 1 Day 3.55 0.40
Low 881.00 1 Week -16.60 -1.84
Close 887.90 1 Month -42.10 -4.53
Volume 284982 1 Year 123.55 16.16
52 Week High 994.00
52 Week Low 671.10
GLENMARK Important Levels
Resistance 2 902.73
Resistance 1 896.62
Pivot 888.63
Support 1 879.18
Support 2 873.07
NSE INDIA Most Active Stocks
JPASSOCIAT 10.20 5.15%
SUZLON 15.70 0.64%
JINDALSTEL 80.20 3.48%
ADANIPOWER 37.85 2.30%
HINDALCO 177.00 3.48%
VEDL 244.40 3.52%
GMRINFRA 12.55 0.00%
BHEL 132.40 3.48%
POWERGRID 198.45 0.35%
NHPC 29.80 -0.50%
NSE INDIA Top Gainers Stocks
RASOYPR 0.20 33.33%
FMNL 45.00 20.00%
INDOTHAI 25.05 19.86%
HOTELRUGBY 4.60 19.48%
OILCOUNTUB 52.05 17.89%
PANACEABIO 148.30 16.59%
ELGIRUBCO 55.95 15.96%
TRIL 437.90 15.42%
WEIZFOREX 244.90 14.81%
JINDCOT 16.85 14.63%
NSE INDIA Top Losers Stocks
VKSPL 0.10 -33.33%
FCSSOFT 0.30 -14.29%
SPYL 1.00 -13.04%
NAKODA 0.40 -11.11%
UNITEDTEA 303.95 -8.55%
AGARIND 332.80 -7.14%
ASIL 0.70 -6.67%
CELESTIAL 21.30 -6.17%
KRIDHANINF 57.75 -6.02%
SUNDARAM 4.05 -5.81%

Glenmark Pharmaceuticals Limited (NSE: GLENMARK)

GLENMARK Technical Analysis 1.5
As on 18th Jan 2017 GLENMARK Share Price closed @ 887.90 and we RECOMMEND Buy for LONG-TERM with Stoploss of 849.15 & Sell for SHORT-TERM with Stoploss of 896.84 we also expect STOCK to react on Following IMPORTANT LEVELS.
GLENMARK Target for January
1st Target up-side 944.5
2nd Target up-side 983.79
3rd Target up-side 1023.08
1st Target down-side 832.4
2nd Target down-side 793.11
3rd Target down-side 753.82
GLENMARK Synopsis Technicals View
50 Day EMA N/A (Short Term)
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
ADX (14) N/A N/A
10 Day Avg Volume N/A
GLENMARK Other Details
Segment EQ
Market Capital 68178259968.00
Sector Healthcare
Industry Drugs - Generic
Offical website
Glenmark House
B D S Marg
Mumbai, 400099
Phone: 91 22 4018 9999
Fax: 91 22 4018 9990
GLENMARK Latest News
Interactive Technical Analysis Chart Glenmark Pharmaceuticals Limited ( GLENMARK NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Glenmark Pharmaceuticals Limited
GLENMARK Business Profile
Glenmark Pharmaceuticals (GPL) is engaged in the research and development, manufacturing and marketing of branded formulations in India and abroad. The company is headquartered at Mumbai and was incorporated in the year 1977 by Gracias Saldanha. Its business segments include India API, exports formulations and API NCE research. The company is present in over 80 countries across the globe, with some of its subsidiaries and representative offices in the United States, the United Kingdom, Switzerland, Brazil, South Africa, Nigeria, Russia, Philippines and Malaysia. It has been involved in new drug discoveries such as new molecules for asthma, obesity and diabetes segments. Glenmark has been involved in API business. Glenmark conducts its operations through its manufacturing plants including Baddi, Goa, Nasik and Sao Paulo, Brazil for formulations and Ankleshwar, Kurkumbh and Solapur for API. Glenmark Pharmaceuticals` research activities encompass process engineering for APIs, new chemical entity research and novel drug delivery systems [NDDS]. The company also operates a second research facility at Sinnar, India that focuses on developing formulations for India and markets across Asia, Africa, Latin America and CIS/Russia. The company is further researching PDE-4 inhibitors for CNS indications, cognitive disorders and inflammatory conditions such as atopic dermatitis, ulcerative colitis and rheumatoid arthritis. Other research areas include diabetes segment in which the company has a DPP-IV target, GRC 8200, in Phase I clinical trials. For the last five years the company has increased its growth through investment in dedicated research and development, including cutting-edge New Chemical Technology (NCE) research. The company currently ranks among the top 20 Indian pharmaceutical firms. The current market capitalization stands at Rs 13,855.67 crore. The company has reported a consolidated sales of Rs 1463.38 crore and a Net Profit of Rs 157.3 crore for the quarter ended September 2013. The company management includes Glenn Saldanha - Chairman & Managing Director, Rajesh V Desai - Executive Director & CFO, Cherylann Pinto - Director - Corporate Affairs, D R Mehta - Non Executive Director, Bernard Munos - Non Executive Director, J F Ribeiro - Non Executive Director, Brian W Tempest - Non Executive Director, Sridhar Gorthi - Non Executive Director, Hocine Sidi Said - Non Executive Director, N B Desai - Non Executive Director. The Registered office is at B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai,Maharashtra - 400026 and corporate office is at Glenmark House, HDO Corporate Building, Wing - A, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri - E, Mumbai - 400099 in MAHARASHTRA.